discussions with the FDA, we currently plan to initiate this trial and enroll patients in 2018.Other Upstream Genetic Defects in the MC4 PathwayWe are also focusing on additional monogenic, upstream MC4 pathway deficiencies for which setmelanotide can function as replacement therapy and
Based on these preliminary discussions with the FDA, we currently plan to initiate this trial and enroll patients in 2018.•Expand setmelanotide development to additional upstream MC4 pathway deficiencies,
we cannot generate positive results in our later clinical trials of setmelanotide, we may be unable to successfully develop, obtain regulatory approval for and commercialize setmelanotide.•The number of patients suffering from each of the MC4 pathway deficiencies is small and has not been established with precision.
than we had estimated, our revenue and ability to achieve profitability will be materially adversely affected.•Failures or delays in the commencement or completion of our planned clinical trials of setmelanotide could result in increased costs to us and
could delay, prevent or limit our ability to generate revenue and continue our business.•Changes in regulatory requirements, FDA guidance or unanticipated events during our clinical trials of setmelanotide may occur, which may
approvals, we will not be able to commercialize setmelanotide and our ability to generate revenue will be materially impaired.•If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could
approved labeling or result in significant negative consequences following marketing approval, if any.•Even if approved, reimbursement policies could limit our ability to sell setmelanotide.•Competing products and technologies could emerge, adversely affecting our opportunity to generate revenue from the sale of setmelanotide.•If we are unable to obtain and maintain patent protection for setmelanotide and its related technology, or if the scope of the patent
Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:•initiate and successfully complete later-stage clinical trials that meet their clinical endpoints;•initiate and successfully complete all safety studies required to obtain U.S. and foreign marketing approval for setmelanotide as a treatment
an independent company and from reduced economies of scale, including changes in cost structure, personnel needs, financing and operations of our business.Risks Related to the Development of SetmelanotidePositive results from early clinical trials of setmelanotide may not be predictive of the results of later
If we cannot generate positive results in our later clinical trials of setmelanotide, we may be unable to successfully develop, obtain regulatory approval for, and
result in increased costs to us and could delay, prevent or limit our ability to generate revenue and continue our business.We completed Phase 2 clinical trials for setmelanotide in 2016 for POMC deficiency obesity and are currently advancing an ongoing pivotal
as the commencement and successful completion of clinical trials can be delayed or prevented for a number of reasons, including but not limited to:•the FDA or other equivalent competent authorities in foreign jurisdictions may deny permission to proceed with our planned Phase 3
clinical trials or any other clinical trials we may initiate, or may place a clinical trial on hold;•delays in filing or receiving approvals or additional IND that may be required;•negative results from our ongoing and planned preclinical studies, or the FDA or other equivalent competent authorities in foreign
required to conduct additional clinical trials, the commercial prospects for setmelanotide may be harmed and our ability to generate product revenue will be delayed.In
for marketing authorization due to the need to limit treatment to rare patient populations, or to safety concerns;•we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of
require substantial financial resources and could delay regulatory approval of setmelanotide.We intend to focus our development of setmelanotide as a treatment for obesity caused by certain genetic deficiencies affecting the MC4 pathway.
indications sought or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of setmelanotide with other available therapies.
are unable to do so on commercially reasonable terms, our business, results of operations, financial condition and prospects would be materially adversely affected.Even if we receive marketing approval for setmelanotide in the United States, we may never receive regulatory
labeling limits the approved population to patients ages 12 and above;•the strength of marketing and distribution support and timing of market introduction of competitive products;34Table of Contents•publicity concerning setmelanotide or competing products and treatments;•pricing and cost effectiveness;•the effectiveness of our sales and marketing strategies;•our ability to increase awareness of setmelanotide through marketing efforts;•our ability to obtain sufficient third-party coverage or reimbursement;•the willingness of patients to pay out-of-pocket in the absence of third-party coverage; and•the likelihood that the FDA or other equivalent competent authorities in foreign jurisdictions may require development of a REMS as a condition